According to the structural analysis, it was initially hypothesized that the AOME may be able to treat gastric cancer through different pathways related to cancer, such as the PI3K-AKT and JAK/STAT signaling pathways; receptor activation, which causes chemical carcinogenesis; microRNAs in cancer; focal adhesion; the Rap1 signaling pathway; resistance to EGFR tyrosine kinase inhibitors; the HIF-1 signaling pathway; the thyroid hormone signaling pathway; the Ras signaling pathway; the relaxin signaling pathway; and gastric cancer. Here, AKT1 is linked to gastric cancer.